Related Experiment Video
Updated: Jun 9, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Insulin Stabilization Designs for Enhanced Therapeutic Efficacy and Accessibility
Yanxian Zhang1, Maxwell Jack Austin1,2, Danny Hung-Chieh Chou1
1Division of Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Stanford University, Stanford, California 94305, United States.
Accounts of Chemical Research
|October 28, 2024
Summary
Researchers developed stable insulin analogs and formulation strategies to improve insulin therapy, addressing challenges like cold-chain requirements and suboptimal patient outcomes for better diabetes management.
Area of Science:
- Protein Engineering and Pharmaceutical Formulation
- Biochemistry and Drug Delivery
Background:
- Insulin therapy for diabetes, vital since 1921, faces challenges due to protein instability, requiring strict cold-chain management.
- Current insulin formulations present a demanding regimen and suboptimal outcomes, necessitating safer, user-friendly alternatives.
- Existing insulin stabilization methods are limited, driving the need for novel approaches compatible with advanced therapies.
Purpose of the Study:
- To engineer novel, stable insulin analogs and explore formulation design strategies for enhanced insulin stability in aqueous solutions.
- To address limitations of conventional insulin stabilization and explore alternative, less invasive administration routes.
- To provide a comprehensive overview of insulin stabilization from industrial and research perspectives.
Main Methods:
- Developed a four-disulfide insulin analog with enhanced aggregation stability and potency.
- Created structurally miniaturized, fully active insulin analogs to promote monomeric state and rapid absorption.
- Investigated cucurbit[7]uril (CB[7])-assisted stabilization with biodegradable polypeptide excipients and explored N-terminal substitution for pH-dependent stabilization.
Main Results:
- Successfully engineered a novel four-disulfide insulin analog demonstrating high stability and potency.
- Developed miniaturized insulin analogs that remain monomeric, paving the way for ultrafast-acting insulins.
- Identified strategies for CB[7]-assisted stabilization and pH-dependent stabilization, expanding insulin formulation possibilities.
Conclusions:
- Novel protein engineering and formulation strategies can significantly improve insulin stability and therapeutic potential.
- These advancements offer a path towards more stable, user-friendly insulin therapies, potentially reducing the self-management burden.
- Continued interdisciplinary efforts in protein engineering, formulation design, and drug delivery are crucial for next-generation insulin therapies.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
171
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
171
01:16Insulin: Dosing Regimen and Adverse Effects
148
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
148
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:25Insulin: Biosynthesis, Chemistry, and Preparation
360
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
360
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176